Mayo Clinic first in U.S. to offer genetic test for lymphoma

Volume 6, Issue 2, 2017

Summary

The Lymph2Cx test for diffuse large B-cell lymphoma offers a new tool in diagnosis and treatment.

Photograph of Keith Stewart, M.B., Ch.B.

Keith Stewart, M.B., Ch.B.

Researchers at Mayo Clinic have created a genetic test to help guide the diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma.

"The Lymph2Cx test helps determine where the lymphoma started," said Keith Stewart, M.B., Ch.B., the Carlson and Nelson Endowed director of the Center for Individualized Medicine at Mayo Clinic.

Mayo Clinic will be the first institution in the United States to offer the Lymph2Cx lymphoma test to patients. The Lymph2Cx test will first be used in clinical practice at Mayo Clinic's new Molecular Diagnostic Laboratory in Arizona, Dr. Stewart said. The lab enables Mayo Clinic physicians and researchers to rapidly access new and existing tests to improve patient care.

The Lymph2Cx test eventually will be available to patients at Mayo Clinic campuses in Florida and Minnesota, too.

Each year, more than 20,000 people in the U.S. are diagnosed with diffuse large B-cell lymphoma, a type of non-Hodgkin's lymphoma, Dr. Stewart said.

"Diagnostic tests such as the Lymph2Cx test will address an unmet need of cancer patients in the U.S. and worldwide," Dr. Stewart said. "New tests like this help us identify accurate diagnoses and treatments quickly, saving time and money, and, ultimately, transforming patient care."

Dr. Stewart is also the Vasek and Anna Maria Polak Professor of Cancer Research in the Division of Hematology-Oncology at Mayo Clinic's campus in Arizona.